Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835159 · ClinicalTrials.gov registry record · Phase 4
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00835159 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT00835159, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.
Interventions
- OTHER Placebo Patch
- DRUG Rivastigmine Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835159
The ClinicalTrials.gov registry entry for NCT00835159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00835159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835159 about?
NCT00835159 is a clinical study titled "Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial". The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.
What is the current status of trial NCT00835159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00835159?
The interventions under investigation include: Placebo Patch (OTHER), Rivastigmine Patch (DRUG).
Who is sponsoring clinical trial NCT00835159?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.